Parsec Financial Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | $25.1M | Sell |
72,956
-4,016
| -5% | -$1.35M | 1.06% | 27 |
|
|
2022
Q4 | $28.2M | Sell |
76,972
-3,406
| -4% | -$1.21M | 1.25% | 23 |
|
|
2022
Q3 | $26M | Sell |
80,378
-6,335
| -7% | -$2.01M | 1.3% | 17 |
|
|
2022
Q2 | $28.1M | Sell |
86,713
-4,725
| -5% | -$1.42M | 1.36% | 17 |
|
|
2022
Q1 | $26.2M | Sell |
91,438
-1,079
| -1% | -$278K | 1.11% | 31 |
|
|
2021
Q4 | $25.6M | Sell |
92,517
-751
| -0.8% | -$190K | 1.06% | 31 |
|
|
2021
Q3 | $24.4M | Buy |
93,268
+2,596
| +3% | +$641K | 1.04% | 33 |
|
|
2021
Q2 | $20.8M | Buy |
90,672
+1,086
| +1% | +$218K | 0.98% | 33 |
|
|
2021
Q1 | $16.7M | Buy |
89,586
+3,437
| +4% | +$672K | 0.86% | 38 |
|
|
2020
Q4 | $14.5M | Buy |
86,149
+2,534
| +3% | +$378K | 0.79% | 39 |
|
|
2020
Q3 | $12.4M | Buy |
83,615
+477
| +0.6% | +$73.8K | 0.75% | 38 |
|
|
2020
Q2 | $13.7M | Sell |
83,138
-3,614
| -4% | -$555K | 0.87% | 35 |
|
|
2020
Q1 | $12M | Buy |
86,752
+1,010
| +1% | +$139K | 0.9% | 38 |
|
|
2019
Q4 | $11.3M | Buy |
85,742
+386
| +0.5% | +$44.7K | 0.66% | 52 |
|
|
2019
Q3 | $9.54M | Sell |
85,356
-3,393
| -4% | -$378K | 0.6% | 56 |
|
|
2019
Q2 | $9.83M | Sell |
88,749
-1,143
| -1% | -$135K | 0.61% | 55 |
|
|
2019
Q1 | $11.7M | Sell |
89,892
-1,976
| -2% | -$240K | 0.74% | 51 |
|
|
2018
Q4 | $10.6M | Sell |
91,868
-1,691
| -2% | -$189K | 0.77% | 50 |
|
|
2018
Q3 | $10M | Buy |
93,559
+4,250
| +5% | +$425K | 0.63% | 55 |
|
|
2018
Q2 | $7.62M | Buy |
89,309
+4,430
| +5% | +$364K | 0.52% | 61 |
|
|
2018
Q1 | $6.57M | Buy |
84,879
+6,117
| +8% | +$492K | 0.45% | 66 |
|
|
2017
Q4 | $6.65M | Buy |
78,762
+20,000
| +34% | +$1.7M | 0.45% | 65 |
|
|
2017
Q3 | $5.03M | Buy |
58,762
+6,057
| +11% | +$497K | 0.36% | 81 |
|
|
2017
Q2 | $4.34M | Buy |
52,705
+8,395
| +19% | +$685K | 0.34% | 86 |
|
|
2017
Q1 | $3.73M | Sell |
44,310
-879
| -2% | -$70.4K | 0.31% | 88 |
|
|
2016
Q4 | $3.32M | Buy |
45,189
+24,636
| +120% | +$1.83M | 0.29% | 90 |
|
|
2016
Q3 | $1.65M | Buy |
20,553
+10,598
| +106% | +$848K | 0.15% | 115 |
|
|
2016
Q2 | $784K | Buy |
9,955
+3,145
| +46% | +$237K | 0.08% | 128 |
|
|
2016
Q1 | $490K | Sell |
6,810
-79
| -1% | -$5.98K | 0.05% | 135 |
|
|
2015
Q4 | $580K | Sell |
6,889
-518
| -7% | -$43K | 0.06% | 131 |
|
|
2015
Q3 | $620K | Buy |
7,407
+2,073
| +39% | +$175K | 0.07% | 125 |
|
|
2015
Q2 | $445K | Hold |
5,334
| – | – | 0.04% | 133 |
|
|
2015
Q1 | $388K | Buy |
5,334
+128
| +2% | +$9.11K | 0.04% | 140 |
|
|
2014
Q4 | $359K | Buy |
5,206
+500
| +11% | +$33.8K | 0.04% | 132 |
|
|
2014
Q3 | $305K | Sell |
4,706
-278
| -6% | -$17.6K | 0.03% | 135 |
|
|
2014
Q2 | $310K | Sell |
4,984
-251
| -5% | -$15K | 0.03% | 134 |
|
|
2014
Q1 | $308K | Hold |
5,235
| – | – | 0.03% | 130 |
|
|
2013
Q4 | $267K | Sell |
5,235
-150
| -3% | -$7.51K | 0.03% | 128 |
|
|
2013
Q3 | $271K | Sell |
5,385
-78
| -1% | -$4.08K | 0.04% | 116 |
|
|
2013
Q2 | $268K | Buy |
+5,463
| New | +$297K | 0.04% | 117 |
|
Other funds holding LLY
Parsec Financial Management's LLY Position: Q1 2023 in Review
Parsec Financial Management reduced its Eli Lilly (LLY) stake by 5.2% in Q1 2023, selling an estimated $1.35M and leaving 72,956 shares worth $25.1M. The position accounts for 1.06% of the portfolio, ranked #27.
Parsec Financial Management first reported a position in LLY in Q2 2013 and has held it in 40 quarters since. The position peaked at $28.2M in Q4 2022. 2,614 funds tracked by Wall St. Rank hold LLY as of Q1 2023.
- Parsec Financial Management held 72,956 shares of Eli Lilly worth $25.1M as of Q1 2023.
- Parsec Financial Management sold 4,016 Eli Lilly shares in Q1 2023, an estimated $1.35M.
- Eli Lilly made up 1.06% of Parsec Financial Management's portfolio in Q1 2023, its #27 holding.
- Parsec Financial Management first reported a position in Eli Lilly in Q2 2013 and has held it in 40 quarters since.
- Parsec Financial Management's Eli Lilly position peaked at $28.2M in Q4 2022.
- 2,614 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2023.
Based on Parsec Financial Management's 13F filing for Q1 2023, filed 6 Apr 2023.